Aortic Stenosis · SAVR vs TAVR
Meets indication → AVR; <65/life expectancy >20 y SAVR, 65-80 shared decision, >80/high-risk TF-TAVR; unsuitable access/concomitant surgery → SAVR.
<65/long expectancy → SAVR: <65 years or life expectancy >20 years → surgical aortic valve replacement (SAVR, mechanical valve an option); access unsuitable for TAVR, …
Step-by-step decision
Choose step by step as prompted; reaching an endpoint gives the management recommendation. You can go back a step or restart anytime.
🎓 Want to practice? Do a case challenge with this pathway → (get a case, choose management step by step, scored).
Full pathway
- [Decision] Intervention indication + age/risk/accessDoes it meet an intervention indication? Age/surgical risk/access? (Intervention indications: symptomatic severe AS; or asymptomatic severe with LVEF <50%, need for other cardiac surgery, abnormal exercise test, very severe/rapid progression, raised BNP.)
- Severe AS, asymptomatic with no indication → Asymptomatic no indication → follow up
- Meets indication, <65 years or life expectancy >20 years → <65/long expectancy → SAVR
- Meets indication, 65–80 years → 65–80 years → shared decision
- Meets indication, >80 years/life expectancy <10 years or high/prohibitive surgical risk → >80/high-risk → TF-TAVR
- [End] Asymptomatic no indication → follow upAsymptomatic severe AS with no indication → close follow-up (echo, symptoms, exercise test, BNP); intervene once an indication appears.
- [End] <65/long expectancy → SAVR<65 years or life expectancy >20 years → surgical aortic valve replacement (SAVR, mechanical valve an option); access unsuitable for TAVR, need for concomitant CABG/other valve/ascending aorta ≥4.5 cm (bicuspid) → SAVR + the relevant procedure.
- [End] 65–80 years → shared decision65–80 years → SAVR or transfemoral TF-TAVR are both Class I, Heart Team shared decision (anatomy, valve durability, lifetime management and reintervention risk).
- [End] >80/high-risk → TF-TAVR>80 years/life expectancy <10 years or high/prohibitive surgical risk (expected post-procedure survival >12 months) → transfemoral TF-TAVR preferred.
Source guidelines & references
- Valvular heart disease management (2020 ACC/AHA; 2021 ESC/EACTS)
This pathway is our own synthesis of the decision logic in the guidelines above (not the guideline verbatim); thresholds and workflows change as guidelines update — in practice follow the latest guideline, your institution's protocol and the individual patient.
Paste the link in Slack, Teams, X, or LinkedIn — the preview image comes from this page’s Open Graph card.